+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials - July 2020

  • ID: 5136766
  • Report
  • July 2020
  • Region: Global
  • 26 pages
  • GlobalData
Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials - July 2020

Summary

Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.

Scope
  • Global overview of changes to clinical practice and clinical trial logistics in H1 2020 in 8MM (US, 5EU, Japan, Canada)
  • Summary of primary research with Immunology Key Opinion Leaders
  • Forward-looking perspective of potential long-term ramifications of COVID pandemic
Reasons to Buy
  • Understand the impact of COVID-19 on immunology clinical trials
  • Obtain a snapshot of the regulatory guidance issued by the US FDA, EMA, and Health Canada
  • Understand the impact of COVID on continuity of care for immunology patients
  • Understand the impact of COVID on clinical trial logistics (including trial recruitment, trial conduct, and supply chain)
  • Understand the potential long-term impact of COVID on clinical trial conduct and clinical practice
Note: Product cover images may vary from those shown
1 Immunology Trials Disrupted
1.1 Overview of Immunology Trials Disrupted
1.2 Regulatory Guidance Across the 8MM

2 KOL Insights: Continuity of Care

3 KOL Insights: Trial Logistics
3.1 Recruitment
3.2 Conduct in Isolation
3.3 Supply Chain

4 KOL Insights: Trials Looking Forward
4.1 Clinical Trials Disrupted Due to COVID
4.2 Immunology Clinical Trials Resumed

5 Appendix
5.1 Sources Used
5.2 About the Authors
5.3 Get in Touch
Note: Product cover images may vary from those shown
Adroll
adroll